About this Journal Submit a Manuscript Table of Contents
Clinical and Developmental Immunology
Volume 2012 (2012), Article ID 340542, 5 pages
http://dx.doi.org/10.1155/2012/340542
Research Article

Thr92Ala Polymorphism of Human Type 2 Deiodinase Gene (hD2) Affects the Development of Graves' Disease, Treatment Efficiency, and Rate of Remission

1Institute of Endocrinology, Almazov Federal Heart, Blood and Endocrinology Centre, 2 Akkuratova Street, Saint-Petersburg 197541, Russia
2Institute of Molecular Biology and Genetics, Almazov Federal Heart, Blood and Endocrinology Centre, 2 Akkuratova Street, Saint-Petersburg 197541, Russia
3Department of Mathematical Modeling, Almazov Federal Heart, Blood and Endocrinology Centre, 2 Akkuratova street, Saint-Petersburg 197541, Russia

Received 14 June 2012; Revised 7 October 2012; Accepted 18 October 2012

Academic Editor: Shervin Assassi

Copyright © 2012 Babenko Alina et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to Cite this Article

Babenko Alina, Popkova Daria, Freylihman Olga, Solncev Vladislav, Kostareva Anna, and Grineva Elena, “Thr92Ala Polymorphism of Human Type 2 Deiodinase Gene (hD2) Affects the Development of Graves' Disease, Treatment Efficiency, and Rate of Remission,” Clinical and Developmental Immunology, vol. 2012, Article ID 340542, 5 pages, 2012. doi:10.1155/2012/340542